# Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

> **NCT07720167** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical University of South Carolina** · enrollment: 38 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Carboplatin + Pemetrexed/Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07720167
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2029-11-01
- **Final completion:** 2030-11-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720167, "Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*